The past decade has seen a sea change in the treatment of prostate cancer. The implementation of genetic sequencing and the rise of targeted therapies have led to tailored treatment regimens and positive outcomes for often even the most advanced disease.
Ahead of the 14th Annual Interdisciplinary Prostate Cancer Congress, ONCOLOGY® sat down with Leonard G. Gomella, MD, professor and chair of Thomas Jefferson University Hospital’s Department of Urology and clinical director of the Sidney Kimmel Cancer Center Network, to discuss 10 years of breakthroughs for patients with prostate cancer and the hope that continued research will fully transform prostate cancer from a deadly disease into a chronic, manageable condition.
Q: Can you discuss some of the recent advances in prostate cancer, and in genitourinary (GU) cancers as a whole?
Gomella: It’s been an amazing 10 years, particularly…
